About Lectus Therapeutics
Lectus Therapeutics was a Healthcare company based in Cambridge (United Kingdom) founded in 2002, and was acquired by UCB in November 2011. It develops innovative small molecule therapeutics for effective pain management. It operates on a B2B model. Lectus Therapeutics has raised $20.35 million across 2 funding rounds from investors including UCB, Wellcome and Sofinnova. The company is recorded as dissolved. Its focus areas include Biotechnology, Therapeutics and Pain Management.
Company details
Lectus Therapeutics develops innovative small molecule therapeutics for effective pain management through providing healthcare solutions, advancing biotech innovations, therapeutics, and pain management. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Cambridge, United Kingdom
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website lectustherapeutics.com
- Acquired by UCB (Nov 2011)
Funding Insights of Lectus Therapeutics
Lectus Therapeutics has successfully raised a total of $20.35M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $6.05 million completed in September 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.35M
- Total Rounds 2
- Last Round Series A — $6.05M
- First Round $14.3M
(Feb 2006)
- Investors Count 4
All 2 funding rounds of Lectus Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2007 | $6.05M | Series A | – | – | |
| Feb 2006 | $14.3M | Series A | – | Sofinnova Partners |
5 investors in total: 5 institutional.
Investors in Lectus Therapeutics
Lectus Therapeutics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include UCB, Wellcome and Sofinnova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Sciences sector focused early stage VC firm investing primarily in Europe | sofinnova.fr | Paris, France | ||
| astellasventure.com | ||||
| takedaventures.com | ||||
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
Therapies for immunological and neurological disorders are developed. | 1928 | ucb.com | Brussels, Belgium |
Investor details for Lectus Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lectus Therapeutics
4 dated milestones of Lectus Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Lectus Therapeutics is founded.
- Funding First funding round of $14.3M.
- Funding Latest funding round, Series A, of $6.0M.
- Exit Acquired by UCB.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lectus Therapeutics
Complete news archive for Lectus Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lectus Therapeutics
Lectus Therapeutics was founded in 2002 and raised its 1st funding round 4 years after it was founded.
Lectus Therapeutics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Lectus Therapeutics is a funded company, having raised a total of $20.35M across 2 funding rounds to date. The company's 1st funding round was a Series A of $14.3M, raised on Feb 2006.
Lectus Therapeutics develops innovative small molecule therapeutics for effective pain management through providing healthcare solutions, advancing biotech innovations, therapeutics, and pain management. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Yes. Lectus Therapeutics was acquired by UCB in November 2011.